Loading news article.

Newsfiscal.ai

Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study

Oct 29, 2026, 09:03 ET · Published

Article summary

Palisade Bio has initiated dosing in its global Phase 2b clinical trial, ASCENTRA-UC, evaluating the efficacy and safety of PALI-2108 in patients with ulcerative colitis.

An excerpt from the original article.

Related companies

Palisade Bio, Inc. Common StockPALIView stock

Analyzed by WAPE AI.

Preparing English content…

Repost

Comments —

Loading comments…